The CTTQ Pharmaceutical Research Institute consists of Nanjing Pharmaceutical Research Center and Lianyugang Pharmaceutical Research Center with Nanjing Pharmaceutical Research Center located in the Xuzhuang Software Industrial Zone at the east foot of Tzu-chin Mountain (Purple Mountain) in Nanjing. Situated at the downtown area of Nanjing city, the Xuzhuang Software Industrial Zone is close to the Zhongshan Mountain Scenic Spot, a 5A-Class national tourist attraction in China. Adjacent to the Shanghai-Nanjing Expressway, Ningbo-Lianyungang Expressway, Airport Expressway, and National Highway 312 (or Xuanwu Highway), it is easily accessible and geographically superior, characterized by an extensive scientific research atmosphere.
With a total investment of 200 million yuan and covering a floor area of 20,000 square meters, the Nanjing Pharmaceutical Research Center is among the largest state-owned pharmaceutical enterprises. Covering an estimated floor space of 10,000 square meters and situated in Lianyungang, a picturesque coastal tourist city in China, the Lianyungang Pharmaceutical Research Center is committed to key scientific research including scientific research and development as well as technical delivery.
The CTTQ Pharmaceutical Research Institute boasts 130 researchers with an average age of 30, including 8 senior engineers, 5 doctors, and 32 masters. Equipped with the Chemical Department, Department of Pharmaceutics, Department of Traditional Chinese Medicine, Department of Pharmaceutical Analysis, Post-doctoral Workstation, and Department of Medical Affairs, the institute is well capable of conducting pharmacy research projects such as technical research on crude drugs, preparations and research on quality standards. At the same time, it can also conduct pharmacological and toxicological research in a variety of fields. Since 2006, it began to engage in the development of bioengineering drugs, which has won initial success.
CTTQ is engaged in scientific research in the following 8 fields of diseases: hepatitis, tumor, diabetes, respiratory disease, cardiovascular and cerebrovascular diseases, anti-infection, digestion, and nerve. In particular, it enjoys unique advantages in the research of hepatic drugs, including drugs for liver protection and enzyme decrease, antiviral drugs, and drugs for immunoregulation; in addition, it has also developed a series of products including drugs for liver fibrosis, hepatic encephalopathy and fatty liver, applicators hepatic diseases, and health care products for liver.
Consistently guided by the concept of “mutual benefit and common development”, CTTQ has established close cooperation with dozens of renowned Chinese scientific research institutes and colleges and universities including Shanghai Institute of Pharmaceutical Industry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The company has made greater efforts in international cooperation and has reached agreement with two American scientific research institutes to develop new drugs. In addition, it also conducts cooperation with the Hong Kong Polytechnic University and Hong Kong Baptist University so as to develop innovative projects like bioengineering drugs and liposome.
The company has always attached great importance to team development and research and development investment with an annual investment in research and development up to 8% of its sales revenue, totaling over 100 million yuan in 2008 and expected to reach 159 million yuan in 2009. In years to come, its investment in research and development will gradually approach the average level of multinational pharmaceutical enterprises.